Form 8-K - Current report:
SEC Accession No. 0001193125-24-211130
Filing Date
2024-08-30
Accepted
2024-08-30 16:21:54
Documents
14
Period of Report
2024-08-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d703760d8k.htm   iXBRL 8-K 28931
2 EX-10.1 d703760dex101.htm EX-10.1 78296
  Complete submission text file 0001193125-24-211130.txt   250772

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20240826.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20240826_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20240826_pre.xml EX-101.PRE 10831
17 EXTRACTED XBRL INSTANCE DOCUMENT d703760d8k_htm.xml XML 3541
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 241270391
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)